Business Context and Reporting Period
Company: Ocular Therapeutix, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 8, 2018
Reporting Period: Quarter and year ended December 31, 2017
Status: Emerging Growth Company (Elected not to use extended transition period)
Key Financial Metrics
The filing serves as a notification of the announcement of financial results for the quarter and year ended December 31, 2017. The specific numerical values for revenue, profit, cash flow, margins, debt, and liquidity are not contained within the text of this Form 8-K. These details are referenced as being included in the press release furnished as Exhibit 99.1.
Material Changes
This document does not provide specific data regarding material changes versus prior periods. It solely references the announcement of results for the period ended December 31, 2017.
Guidance, Outlook, and Risks
The filing does not contain specific guidance, outlook, management commentary, or risk factors within its text. It incorporates the press release (Exhibit 99.1) by reference for these details. The filing includes a standard disclaimer that the information is furnished to comply with Item 2.02 and is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 8, 2018) for actual revenue, net loss, and cash position figures.
- Verify the specific details of the "Results of Operations" referenced in Item 2.02.
- Confirm the company's status as an Emerging Growth Company and its election regarding accounting standard transition periods.
- Check subsequent filings for any updates to the financial data announced in this report.